MedDataX Logo

Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Subjects With Hepatitis C Related Liver Disease

NCT ID: NCT00516321

Last Updated: 2013-11-05

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

687 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-10-31

Study Completion Date

2011-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess the ability of eltrombopag to maintain a platelet count sufficient to facilitate initiation of antiviral therapy, to minimise antiviral therapy dose reductions and to avoid permanent discontinuation of antiviral therapy. The clinical benefit of eltrombopag will be measured by the proportion of subjects who are able to achieve a Sustained Virological Response (SVR).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatitis C, Chronic

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

thrombopoietin hepatitis C ribavirin platelets Hepatitis C-related thrombocytopenia peginterferon alfa-2a

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

eltrombopag

25, 50, 75, 100 mg tablets taken once daily orally

Intervention Type DRUG

placebo

matched placebo taken once daily orally

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Male and female subjects, \>18 years Evidence of chronic hepatitis C virus (HCV) infection Subjects who are appropriate candidates for peginterferon (pegIFN) and ribavirin antiviral therapy A platelet count of \<75,000/mcL Haemoglobin \>11.0g/dL for men or \>10.0g/dL for women Absolute neutrophil count (ANC) \>750/mm3 and no history of infections associated with neutropenia Creatinine clearance \>50mL/minute All fertile males and females must use two forms of effective contraception between them during treatment and during the 24 weeks after treatment end Subject is able to understand, consent and comply with protocol requirements and instructions and is likely to complete the study as planned

Exclusion Criteria

Non-responders to previous treatment with pegIFN and ribavirin who failed to achieve a sustained virologic response (SVR) for reasons other than thrombocytopenia, despite an optimal course (dose and duration) of combination therapy with pegIFN and ribavirin Decompensated liver disease, e.g. Child-Pugh score \>6 or history of ascites or hepatic encephalopathy or current evidence of ascites Known hypersensitivity, intolerance or allergy to interferon (IFN), ribavirin, eltrombopag or any of their ingredients Serious cardiac, cerebrovascular, or pulmonary disease that would preclude treatment with pegIFN and ribavirin

Subjects with a history of any one of the following:

Suicide attempt or hospitalisation for depression in the past 5 years Any current severe or poorly controlled psychiatric disorder

The following subjects are eligible for study participation, but must be assessed and followed (if recommended) by a mental health professional:

* Subjects who have had a severe or poorly controlled psychiatric disorder more than 6 months ago but less than 5 years ago
* Seizure disorder that has not been well controlled History of clinically significant bleeding from oesophageal or gastric varices Subjects with haemoglobinopathies, e.g. sickle cell anaemia, thalassemia major Any prior history of arterial or venous thrombosis AND two or more of the following risk factors: hereditary thrombophilic disorders (e.g. Factor V Leiden, antithrombin III (ATIII) deficiency, etc), hormone replacement therapy, systemic contraception (containing estrogen), smoking, diabetes, hypercholesterolemia, medication for hypertension or cancer Pre-existing cardiac disease (New York Heart Association (NYHA) Grade III/IV), or arrhythmias known to involve the risk of thromboembolic events, or corrected QT interval (QTc) \>450 msec Evidence of hepatocellular carcinoma Laboratory evidence of infection with human immunodeficiency virus (HIV) or active Hepatitis B Virus (HBV) infection Any disease condition associated with active bleeding or requiring anticoagulation with heparin or warfarin Therapy with any anti-neoplastic or immuno-modulatory treatment \<6 months prior to the first dose of eltrombopag Subjects who have had a malignancy diagnosed and/or treated within the past 5 years, except for subjects with localised basal or squamous cell carcinoma treated by local excision or subjects with malignancies who have been adequately treated and, in the opinion of the oncologist, have an excellent chance of cancer-free survival Pregnant or nursing women Males with a female partner who is pregnant History of alcohol/drug abuse or dependence within 6 months of the study start (unless participating in a controlled rehabilitation programme) Treatment with an investigational drug or IFN within 30 days or 5 half-lives (whichever is longer) of the screening visit History of platelet clumping that prevents reliable measurement of platelet counts History of major organ transplantation with an existing functional graft Thyroid dysfunction not adequately controlled Subjects planning to have cataract surgery Evidence of portal vein thrombosis on abdominal imaging within 3 months of the baseline visit
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

GlaxoSmithKline

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

GSK Clinical Trials

Role: STUDY_DIRECTOR

GlaxoSmithKline

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

GSK Investigational Site

Birmingham, Alabama, United States

Site Status

GSK Investigational Site

Tucson, Arizona, United States

Site Status

GSK Investigational Site

Little Rock, Arkansas, United States

Site Status

GSK Investigational Site

La Jolla, California, United States

Site Status

GSK Investigational Site

Los Angeles, California, United States

Site Status

GSK Investigational Site

Los Angeles, California, United States

Site Status

GSK Investigational Site

San Clemente, California, United States

Site Status

GSK Investigational Site

Aurora, Colorado, United States

Site Status

GSK Investigational Site

New Haven, Connecticut, United States

Site Status

GSK Investigational Site

Washington D.C., District of Columbia, United States

Site Status

GSK Investigational Site

Washington D.C., District of Columbia, United States

Site Status

GSK Investigational Site

Bradenton, Florida, United States

Site Status

GSK Investigational Site

Gainsville, Florida, United States

Site Status

GSK Investigational Site

Miami, Florida, United States

Site Status

GSK Investigational Site

Orlando, Florida, United States

Site Status

GSK Investigational Site

Atlanta, Georgia, United States

Site Status

GSK Investigational Site

Honolulu, Hawaii, United States

Site Status

GSK Investigational Site

Louisville, Kentucky, United States

Site Status

GSK Investigational Site

Baltimore, Maryland, United States

Site Status

GSK Investigational Site

Burlington, Massachusetts, United States

Site Status

GSK Investigational Site

Worcester, Massachusetts, United States

Site Status

GSK Investigational Site

Ann Arbor, Michigan, United States

Site Status

GSK Investigational Site

Detroit, Michigan, United States

Site Status

GSK Investigational Site

Jackson, Mississippi, United States

Site Status

GSK Investigational Site

St Louis, Missouri, United States

Site Status

GSK Investigational Site

Manhasset, New York, United States

Site Status

GSK Investigational Site

New York, New York, United States

Site Status

GSK Investigational Site

Rochester, New York, United States

Site Status

GSK Investigational Site

Syracuse, New York, United States

Site Status

GSK Investigational Site

The Bronx, New York, United States

Site Status

GSK Investigational Site

Valhalla, New York, United States

Site Status

GSK Investigational Site

Asheville, North Carolina, United States

Site Status

GSK Investigational Site

Durham, North Carolina, United States

Site Status

GSK Investigational Site

Tulsa, Oklahoma, United States

Site Status

GSK Investigational Site

Portland, Oregon, United States

Site Status

GSK Investigational Site

Hershey, Pennsylvania, United States

Site Status

GSK Investigational Site

Philadelphia, Pennsylvania, United States

Site Status

GSK Investigational Site

Jackson, Tennessee, United States

Site Status

GSK Investigational Site

Nashville, Tennessee, United States

Site Status

GSK Investigational Site

Nashville, Tennessee, United States

Site Status

GSK Investigational Site

Nashville, Tennessee, United States

Site Status

GSK Investigational Site

Galveston, Texas, United States

Site Status

GSK Investigational Site

Houston, Texas, United States

Site Status

GSK Investigational Site

San Antonio, Texas, United States

Site Status

GSK Investigational Site

Charlottesville, Virginia, United States

Site Status

GSK Investigational Site

Fairfax, Virginia, United States

Site Status

GSK Investigational Site

Richmond, Virginia, United States

Site Status

GSK Investigational Site

Garran, Australian Capital Territory, Australia

Site Status

GSK Investigational Site

Camperdown, New South Wales, Australia

Site Status

GSK Investigational Site

Randwick, New South Wales, Australia

Site Status

GSK Investigational Site

Fitzroy, Victoria, Australia

Site Status

GSK Investigational Site

Heidelberg, Victoria, Australia

Site Status

GSK Investigational Site

Melbourne, Victoria, Australia

Site Status

GSK Investigational Site

Nedlands, Western Australia, Australia

Site Status

GSK Investigational Site

Brussels, , Belgium

Site Status

GSK Investigational Site

Edegem, , Belgium

Site Status

GSK Investigational Site

Ghent, , Belgium

Site Status

GSK Investigational Site

Leuven, , Belgium

Site Status

GSK Investigational Site

Campinas, São Paulo, Brazil

Site Status

GSK Investigational Site

São Paulo, São Paulo, Brazil

Site Status

GSK Investigational Site

Calgary, Alberta, Canada

Site Status

GSK Investigational Site

Victoria, British Columbia, Canada

Site Status

GSK Investigational Site

Winnipeg, Manitoba, Canada

Site Status

GSK Investigational Site

Barrie, Ontario, Canada

Site Status

GSK Investigational Site

Hamilton, Ontario, Canada

Site Status

GSK Investigational Site

Hamilton, Ontario, Canada

Site Status

GSK Investigational Site

Ottawa, Ontario, Canada

Site Status

GSK Investigational Site

Ottawa, Ontario, Canada

Site Status

GSK Investigational Site

Toronto, Ontario, Canada

Site Status

GSK Investigational Site

Toronto, Ontario, Canada

Site Status

GSK Investigational Site

Toronto, Ontario, Canada

Site Status

GSK Investigational Site

Toronto, Ontario, Canada

Site Status

GSK Investigational Site

Montreal, Quebec, Canada

Site Status

GSK Investigational Site

Montreal, Quebec, Canada

Site Status

GSK Investigational Site

Prague, , Czechia

Site Status

GSK Investigational Site

Prague, , Czechia

Site Status

GSK Investigational Site

Besançon, , France

Site Status

GSK Investigational Site

Dijon, , France

Site Status

GSK Investigational Site

Marseille, , France

Site Status

GSK Investigational Site

Montpellier, , France

Site Status

GSK Investigational Site

Nice, , France

Site Status

GSK Investigational Site

Pessac, , France

Site Status

GSK Investigational Site

Strasbourg, , France

Site Status

GSK Investigational Site

Toulouse, , France

Site Status

GSK Investigational Site

Toulouse, , France

Site Status

GSK Investigational Site

Freiburg im Breisgau, Baden-Wurttemberg, Germany

Site Status

GSK Investigational Site

Heidelberg, Baden-Wurttemberg, Germany

Site Status

GSK Investigational Site

Stuttgart, Baden-Wurttemberg, Germany

Site Status

GSK Investigational Site

Ulm, Baden-Wurttemberg, Germany

Site Status

GSK Investigational Site

Deggendorf, Bavaria, Germany

Site Status

GSK Investigational Site

Hof/Saale, Bavaria, Germany

Site Status

GSK Investigational Site

Munich, Bavaria, Germany

Site Status

GSK Investigational Site

Regensburg, Bavaria, Germany

Site Status

GSK Investigational Site

Würzburg, Bavaria, Germany

Site Status

GSK Investigational Site

Beeskow, Brandenburg, Germany

Site Status

GSK Investigational Site

Frankfurt am Main, Hesse, Germany

Site Status

GSK Investigational Site

Kassel, Hesse, Germany

Site Status

GSK Investigational Site

Göttingen, Lower Saxony, Germany

Site Status

GSK Investigational Site

Hanover, Lower Saxony, Germany

Site Status

GSK Investigational Site

Hanover, Lower Saxony, Germany

Site Status

GSK Investigational Site

Aachen, North Rhine-Westphalia, Germany

Site Status

GSK Investigational Site

Bochum, North Rhine-Westphalia, Germany

Site Status

GSK Investigational Site

Bonn, North Rhine-Westphalia, Germany

Site Status

GSK Investigational Site

Cologne, North Rhine-Westphalia, Germany

Site Status

GSK Investigational Site

Dortmund, North Rhine-Westphalia, Germany

Site Status

GSK Investigational Site

Düsseldorf, North Rhine-Westphalia, Germany

Site Status

GSK Investigational Site

Essen, North Rhine-Westphalia, Germany

Site Status

GSK Investigational Site

Herne, North Rhine-Westphalia, Germany

Site Status

GSK Investigational Site

Leverkusen, North Rhine-Westphalia, Germany

Site Status

GSK Investigational Site

Münster, North Rhine-Westphalia, Germany

Site Status

GSK Investigational Site

Siegen, North Rhine-Westphalia, Germany

Site Status

GSK Investigational Site

Mainz, Rhineland-Palatinate, Germany

Site Status

GSK Investigational Site

Leipzig, Saxony, Germany

Site Status

GSK Investigational Site

Leipzig, Saxony, Germany

Site Status

GSK Investigational Site

Halle, Saxony-Anhalt, Germany

Site Status

GSK Investigational Site

Magdeburg, Saxony-Anhalt, Germany

Site Status

GSK Investigational Site

Berlin, State of Berlin, Germany

Site Status

GSK Investigational Site

Berlin, State of Berlin, Germany

Site Status

GSK Investigational Site

Pokfulam, , Hong Kong

Site Status

GSK Investigational Site

Bangalore, , India

Site Status

GSK Investigational Site

Chennai, , India

Site Status

GSK Investigational Site

Mumbai, , India

Site Status

GSK Investigational Site

Haifa, , Israel

Site Status

GSK Investigational Site

Jerusalem, , Israel

Site Status

GSK Investigational Site

Petah Tikva, , Israel

Site Status

GSK Investigational Site

Safed, , Israel

Site Status

GSK Investigational Site

Tel Aviv, , Israel

Site Status

GSK Investigational Site

Bari, Apulia, Italy

Site Status

GSK Investigational Site

San Giovanni Rotondo (FG), Apulia, Italy

Site Status

GSK Investigational Site

Catanzaro, Calabria, Italy

Site Status

GSK Investigational Site

Avellino, Campania, Italy

Site Status

GSK Investigational Site

Bologna, Emilia-Romagna, Italy

Site Status

GSK Investigational Site

Rome, Lazio, Italy

Site Status

GSK Investigational Site

Genoa, Liguria, Italy

Site Status

GSK Investigational Site

Brescia, Lombardy, Italy

Site Status

GSK Investigational Site

Milan, Lombardy, Italy

Site Status

GSK Investigational Site

Milan, Lombardy, Italy

Site Status

GSK Investigational Site

Palermo, Sicily, Italy

Site Status

GSK Investigational Site

Amsterdam, , Netherlands

Site Status

GSK Investigational Site

Nijmegen, , Netherlands

Site Status

GSK Investigational Site

Rotterdam, , Netherlands

Site Status

GSK Investigational Site

Lahore, , Pakistan

Site Status

GSK Investigational Site

Lahore, , Pakistan

Site Status

GSK Investigational Site

Bydgoszcz, , Poland

Site Status

GSK Investigational Site

Chorzów, , Poland

Site Status

GSK Investigational Site

Kielce, , Poland

Site Status

GSK Investigational Site

Szczecin, , Poland

Site Status

GSK Investigational Site

Wroclaw, , Poland

Site Status

GSK Investigational Site

Ponce, Puerto Rico, Puerto Rico

Site Status

GSK Investigational Site

San Juan, Puerto Rico, Puerto Rico

Site Status

GSK Investigational Site

Bucharest, , Romania

Site Status

GSK Investigational Site

Constanța, , Romania

Site Status

GSK Investigational Site

Moscow, , Russia

Site Status

GSK Investigational Site

Moscow, , Russia

Site Status

GSK Investigational Site

Mosocow, , Russia

Site Status

GSK Investigational Site

Smolensk, , Russia

Site Status

GSK Investigational Site

Bratislava, , Slovakia

Site Status

GSK Investigational Site

Bratislava, , Slovakia

Site Status

GSK Investigational Site

Košice, , Slovakia

Site Status

GSK Investigational Site

Martin, , Slovakia

Site Status

GSK Investigational Site

Busan, , South Korea

Site Status

GSK Investigational Site

Incheon, , South Korea

Site Status

GSK Investigational Site

Seoul, , South Korea

Site Status

GSK Investigational Site

A Coruña, , Spain

Site Status

GSK Investigational Site

Barcelona, , Spain

Site Status

GSK Investigational Site

Granada, , Spain

Site Status

GSK Investigational Site

L'Hospitalet de Llobregat. Barcelona, , Spain

Site Status

GSK Investigational Site

Madrid, , Spain

Site Status

GSK Investigational Site

Madrid, , Spain

Site Status

GSK Investigational Site

Madrid, , Spain

Site Status

GSK Investigational Site

Madrid, , Spain

Site Status

GSK Investigational Site

San Sebastián, , Spain

Site Status

GSK Investigational Site

Seville, , Spain

Site Status

GSK Investigational Site

Valencia, , Spain

Site Status

GSK Investigational Site

Kaohsiung City, , Taiwan

Site Status

GSK Investigational Site

Taichung, , Taiwan

Site Status

GSK Investigational Site

Tainan City, , Taiwan

Site Status

GSK Investigational Site

Taipei, , Taiwan

Site Status

GSK Investigational Site

Bangkok, , Thailand

Site Status

GSK Investigational Site

Bangkok, , Thailand

Site Status

GSK Investigational Site

Chiang Mai, , Thailand

Site Status

GSK Investigational Site

Khon Kaen, , Thailand

Site Status

GSK Investigational Site

Songkhla, , Thailand

Site Status

GSK Investigational Site

Donetsk, , Ukraine

Site Status

GSK Investigational Site

Kyiv, , Ukraine

Site Status

GSK Investigational Site

Kyiv, , Ukraine

Site Status

GSK Investigational Site

Vinnytsia, , Ukraine

Site Status

GSK Investigational Site

Glasgow, Lanarkshire, United Kingdom

Site Status

GSK Investigational Site

London, , United Kingdom

Site Status

GSK Investigational Site

London, , United Kingdom

Site Status

GSK Investigational Site

Plymouth, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Austria Egypt New Zealand United States Australia Belgium Brazil Canada Czechia France Germany Hong Kong India Israel Italy Netherlands Pakistan Poland Puerto Rico Romania Russia Slovakia South Korea Spain Taiwan Thailand Ukraine United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Saleh MI, Obeidat AR, Anter HA, Khanfar AA. Eltrombopag dose predictors in thrombocytopenic subjects with hepatitis C virus infection. Clin Exp Pharmacol Physiol. 2015 Oct;42(10):1030-5. doi: 10.1111/1440-1681.12451.

Reference Type DERIVED
PMID: 26173631 (View on PubMed)

Giannini EG, Afdhal NH, Sigal SH, Muir AJ, Reddy KR, Vijayaraghavan S, Elkashab M, Romero-Gomez M, Dusheiko GM, Iyengar M, Vasey SY, Campbell FM, Theodore D. Non-cirrhotic thrombocytopenic patients with hepatitis C virus: Characteristics and outcome of antiviral therapy. J Gastroenterol Hepatol. 2015 Aug;30(8):1301-8. doi: 10.1111/jgh.12942.

Reference Type DERIVED
PMID: 25777337 (View on PubMed)

Afdhal NH, Dusheiko GM, Giannini EG, Chen PJ, Han KH, Mohsin A, Rodriguez-Torres M, Rugina S, Bakulin I, Lawitz E, Shiffman ML, Tayyab GU, Poordad F, Kamel YM, Brainsky A, Geib J, Vasey SY, Patwardhan R, Campbell FM, Theodore D. Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy. Gastroenterology. 2014 Feb;146(2):442-52.e1. doi: 10.1053/j.gastro.2013.10.012. Epub 2013 Oct 12.

Reference Type DERIVED
PMID: 24126097 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

TPL103922

Identifier Type: -

Identifier Source: org_study_id